E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers S > Headlines for Salix Pharmaceuticals Ltd. > News item
Published on 11/14/2008 in the Prospect News Special Situations Daily.

Baker Bros. Investments increases stake to 9.7% in Salix

By E. Janene Geiss

Philadelphia, Nov. 14 - Baker Bros. Investments II, LP increased its investment to 9.7% in Salix Pharmaceuticals, Ltd. as of Nov. 14, according to an SC 13G/A filing with the Securities and Exchange Commission.

That represents a passive stake of 4,805,729 shares.

Those holdings are up from a passive stake of 7.6%, or 3,858,043 shares, that Baker Bros. initially reported on Aug. 22, 2008, according to an SC 13G filing.

Based in Raleigh, N.C., Salix makes and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.